Pandemic Influenza Vaccine H5N1 Baxter AG Európska únia - slovenčina - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 baxter ag

resilience biomanufacturing ireland limited - vakcína proti chrípke (celý virion, inaktivovaná) obsahujúca antigén: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vakcíny - profylaxia chrípky v oficiálne deklarovanej pandemickej situácii. pandemická očkovacia látka proti chrípke sa má používať v súlade s oficiálnymi pokynmi.

Omeprazol Mylan 20 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

omeprazol mylan 20 mg

mylan ireland limited - omeprazol - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

Pantoprazol Mylan 40 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pantoprazol mylan 40 mg

mylan ireland limited, Írsko - pantoprazol - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

Pantoprazol Mylan 20 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pantoprazol mylan 20 mg

mylan ireland limited, Írsko - pantoprazol - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

Rupatadine Mylan 10 mg tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

rupatadine mylan 10 mg tablety

mylan ireland limited, Írsko - rupatadín - 24 - antihistaminica, histamin

Zejula Európska únia - slovenčina - EMA (European Medicines Agency)

zejula

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastické činidlá - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Volibris Európska únia - slovenčina - EMA (European Medicines Agency)

volibris

glaxosmithkline (ireland) limited - ambrisentan - hypertenzia, pľúca - antihypertenzív, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.

Orkambi Európska únia - slovenčina - EMA (European Medicines Agency)

orkambi

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - orkambi tablety sú uvedené pre liečbu cystickej fibrózy (cf) u pacientov vo veku 6 rokov a starších, ktorí sú homozygous pre f508del mutácie v cftr géne. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Kaftrio Európska únia - slovenčina - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Symkevi Európska únia - slovenčina - EMA (European Medicines Agency)

symkevi

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.